Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus dosing algorithm study in pediatric kidney transplant recipients
NL-OMON27765Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant immunosuppression, sponsored by Erasmus MC. Primary endpoint: Percentage within tacrolimus target predose concentration range. Started Nov 2017; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on NL-OMON27765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27765.